Please login to the form below

Not currently logged in
Email:
Password:

Argenx

This page shows the latest Argenx news and features for those working in and with pharma, biotech and healthcare.

AbbVie to develop argenx-partnered GARP-targeted immunotherapy

AbbVie to develop argenx-partnered GARP-targeted immunotherapy

AbbVie to develop argenx-partnered GARP-targeted immunotherapy. Will build on an initial $60m deal with the biotech. ... So with this new mechanism, argenx is hoping that its candidate can modulate the body’s own immune system to attack cancer cells.

Latest news

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    CytomX leads. Argenx undertakes R&D until IND, AbbVie thereafter it option exercised. ... However the argenx deal is an option not a license and has lower royalty rates.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics